Shire Buys Fosrenol Patent Rights for Up to $31 M

Law360, New York (March 23, 2004, 12:00 AM EST) -- Shire Pharmaceuticals Group Plc, the U.K.'s third-largest drugmaker, will spend up to $31 million to buy global patent rights to its kidney-failure drug Fosrenol from AnorMED, the company said.

Shire will pay AnorMED $18 million when Fosrenol is approved in the U.S. and $7 million when it's approved in European Union, the company said.

The agreement also gives Shire a 12-month option to purchase the Japanese patents for $6 million when the drug is approved in Japan.

Shire will no longer have royalty obligations to AnorMED...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.